Neovacs acquires Interferon Alpha manufacturing technology from AMEGABIOTECH
Neovacs, a manufacturer of active immunotherapies for the treatment of autoimmune diseases, announced an agreement with the Argentinean company AMEGABIOTECH to acquire its interferon Alpha (IFNα) manufacturing license. IFNα is a key component of Neovacs' lead therapeutic candidate, IFNα Kinoid, which is composed of inactivated IFNα coupled with a carrier protein, keyhole limpet hemocyanin.
Miguel Sieler, CEO of Neovacs, commented: "With this agreement, the company has reinforced its ability to maintain control of its technology, quality control, manufacturing and costs, which is key to our overall growth strategy as we continue advancing the clinical development of our lead candidate IFNα Kinoid. With greater control over our Kinoid technology, we can drive optimization of manufacturing costs and more effectively support the potential commercialization of IFNα Kinoid for the treatment of lupus, a complex autoimmune disease where medical needs are urgent and unmet today."
AMEGABIOTECH is a leading global producer of IFNα protein and a long term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNα Kinoid in Lupus. Their product is recognized by the international biotechnology and pharmaceutical industry for the quality of its technological manufacturing, which also meets all relevant international standards for GMP (Good manufacturing Practice).
Other news from the department business & finance
